Ticagrelor vs clopidogrel on vein graft patency in patients with diabetes undergoing coronary artery bypass grafting
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUNDPatients with type 2 diabetes mellitus (T2DM) undergoing coronary artery bypass grafting (CABG) are at high risk of saphenous vein graft (SVG) failure.The optimal antiplatelet therapy for maintaining SVG patency in this population remains uncertain. AIMTo investigate whether ticagrelor plus aspirin is associated with better 5-year SVG patency than clopidogrel plus aspirin in patients with T2DM who undergo CABG. CONCLUSIONAmong 5-year survivors with T2DM who underwent CABG, ticagrelor plus aspirin was associated with better 5-year SVG grade A patency than clopidogrel plus aspirin.This is an uncontrolled observational association, and the estimand is limited to patients who survived to the 5-year CTA.The MACE and BE are inconclusive.These findings do not establish causality, superiority, or equivalent safety.Adequately powered, multicenter, prospective randomized controlled trials are required.
Source: World Journal of Diabetes
DOI: 10.4239/wjd.125765
Institution: Changhai Hospital
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Award: G3105441695
OpenAlex ID: W7236083619
